Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587622 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04587622 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT04587622, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.
Interventions
- DRUG Icenticaftor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04587622
The ClinicalTrials.gov registry entry for NCT04587622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icenticaftor is the first listed.
NCT04587622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04587622 about?
NCT04587622 is a clinical study titled "Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment". The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.
What is the current status of trial NCT04587622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-30. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04587622?
The interventions under investigation include: Icenticaftor (DRUG).
Who is sponsoring clinical trial NCT04587622?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.